Abstract 5117
Background
Monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratio are considered prognostic tools of overall survival (OS) in several hematologic and solid tumors. All these elements have been implicated as biomarkers of tumor microenvironment and immune homeostasis. Mantle cell lymphoma (MCL) is a relatively uncommon subtype of lymphoid malignancy (5%–7% of malignant lymphoma) but could be very aggressive. Mantle Cell Lymphoma International Prognostic Index (MIPI) is the only validated prognostic tool for these patients. The aim of this study assessed the prognostic significance of monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratio as prognostic biomarkers for MCL.
Methods
An observational retrospective study was conducted and included a total all the patients diagnosed with MCL between 2008-2018 in our hematologic center. The ratios were calculated, and statistical analysis were assessed using Kaplan-Meier method, log-rank test and Cox regression. All the analyses were performed using SPSS.
Results
A total of 52 patients were included, 75% were male, with the median age at diagnosis being 67 years-old (max 94, min 36 years old). 77% of the patients had an ECOG PS 0-1, 67% had a high risk MIPI and 73% were a stage IV disease at diagnosis. Kaplan-Meier analysis showed that MIPI score significantly predicts the OS of the patients, with the higher scores being associated with inferior OS (p = 0,02). The same did not happen with the monocyte-lymphocyte ratio (p = 0,5), neutrophil-lymphocyte ratio (p = 0,4) and platelet-lymphocyte ratio (p = 0,3). The same results were showed in cox regression, MIPI score remained the only score associated with OS (HR, 0,35; 95% CI 0,132-0,962).
Conclusions
In conclusion, this study fails to identify monocyte-lymphocyte, neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic tools and support MIPI as predictor of the survival outcome in MCL patients and its ability to identify high-risk patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2490 - Gender effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of anamorelin (ANAM) in healthy volunteers and cancer patients with cachexia
Presenter: Stein Kaasa
Session: Poster Display session 1
Resources:
Abstract
4294 - The Patient Voice: An Irish Survey of Nutrition Attitudes & Access to Dietetic Care Throughout the Cancer Journey
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
1925 - Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients
Presenter: Claudio Chini
Session: Poster Display session 1
Resources:
Abstract
4701 - Treatment-related adverse events and tolerability in patients with advanced non-squamous non-small cell lung cancer treated with first-line checkpoint inhibitors in combination with chemotherapy
Presenter: Ruth D'cunha
Session: Poster Display session 1
Resources:
Abstract
2985 - Clinical utility of a systematic toxicity assessment form (STAF) in patients with breast cancer receiving adjuvant or neoadjuvant therapy.
Presenter: Jwa Hoon Kim
Session: Poster Display session 1
Resources:
Abstract
2358 - Physicians’ satisfaction with Health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients.
Presenter: Guillaume Mouillet
Session: Poster Display session 1
Resources:
Abstract
5172 - Predictors of Survival in Patients with Incurable Cancer
Presenter: Erin Stella Sullivan
Session: Poster Display session 1
Resources:
Abstract
2281 - Patients and Physicians' Satisfaction with Telemedicine (TM) in Cancer Care and Factors that Correlate with a Positive Patient’s Experience
Presenter: Hurria Gondal
Session: Poster Display session 1
Resources:
Abstract
2193 - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: real-world insights from practicing European physicians
Presenter: Alex Rider
Session: Poster Display session 1
Resources:
Abstract
2200 - Use of skeletal-related events preventive agents in patients with solid tumours and bone metastases in central Denmark
Presenter: Anders Boysen
Session: Poster Display session 1
Resources:
Abstract